Browsing by Author "Oğuz A."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Trigliserit nedir? Normal fizyolojideki yeri nedir?
    (Turkish Society of Cardiology, 2017) Çetinkalp Ş.; Koylan N.; Özer N.; Onat A.; Gökhan Özgen A.; Lale Koldaş Z.; Güven G.S.; Özdoğan Ö.; Karşıdağ K.; Yiğit Z.; Kayıkçıoğlu M.; Tokgözoğlu L.; Can L.H.; Tartan Z.; Kültürsay H.; Karpuz B.; Kırılmaz B.; Ersanlı M.; Ural D.; Erbakan A.N.; Oğuz A.; Kayıkçıoğlu Ö.R.; Temizhan A.; Sansoy V.; Ceyhan C.; Öngen Z.; Bayram F.; Örem C.; Sönmez A.; Beyaz Ş.; Ükinç K.; Yürekli B.Ş.; Çoker M.; Canda E.; Şimşir I.Y.
    [No abstract available]
  • No Thumbnail Available
    Item
    The effect of cardiometabolic control and malnutrition on the prevalence and prognosis of diabetic retinopathy in type 2 diabetes; [Tip 2 diyabette kardiyometabolik kontrol ve malnütrisyonun diyabetik retinopati prevalansı ve prognozuna etkisi]
    (Pamukkale University, 2024) Özdemir M.; Dağ Y.; Uzunlulu M.; Oğuz A.; Ardagil A.; Acar Ö.; Selbest B.
    Purpose: This study aims to investigate the predictive value of cardiometabolic control, gamma glutamyl transferase (GGT) and malnutrition-related inflammation markers for predicting diabetic retinopathy (DR) prevalence and prognosis. Materials and methods: Type 2 Diabetes Mellitus patients who were consecutively admitted to Internal and Ophthalmology outpatient clinics were included in this study. Clinical, haematological and biochemical data were recorded. Cut-off values of GGT, hemoglobin, albumin, lymphocyte and platelet (HALP) score, nutritional risk index (NRI) and prognostic nutritional index (PNI) scores were determined by receiver operator characteristic curve analysis. Univariate and multivariate analyses were performed to determine the association of all variables with DR. We evaluated which of these tests were predictive and prognostic for the development of DR. Results: This study included 166 patients. Fasting blood glucose (p<0.001), creatinine (p=0.01), HbA1c (p<0.001) and microalbuminuria (p=0.01) were higher in patients with retinopathy. Mean arterial pressure (p=0.01), fasting blood glucose (p=0.03), triglyceride (p=0.008), body mass index (BMI) (p=0.02) and HbA1c (p=0.04) increased significantly as GGT level increased. Contrary to the literature, HALP, PNI and NRI scores were not associated with DR. Conclusion: Duration of diabetes, cardiometabolic control and GGT level are variables with predictive value for the prognosis of DR. No significant correlation was found between malnutrition-related inflammation markers and DR development and stage. © 2024, Pamukkale University. All rights reserved.
  • No Thumbnail Available
    Item
    Effectiveness and Safety of Initiation and Titration of Insulin Glargine 300 U/mL in Insulin-Naive Patients with Type 2 Diabetes Mellitus Uncontrolled on Oral Antidiabetic Drug Treatment in Turkey: The EASE Study
    (AVES, 2024) Çetinarslan B.; Çetinkalp Ş.; Kaya A.; Ersoy C.; Kebapçı N.; Çömlekçi A.; Tütüncü N.B.; Deyneli O.; Oğuz A.; İlkova H.; Yılmaz T.; Hekimsoy Z.; Ünübol M.; Balcı M.K.; Atmaca A.; Dağdelen S.; Yetkin İ.; Güler S.; Ötünç G.; Özhan L.
    Objective: The aim of the study was to evaluate the effectiveness and safety of insulin glargine 300 U/ mL (Gla-300) in insulin-naive patients with type 2 diabetes mellitus (T2DM) inadequately controlled on oral antidiabetic drug (OADs) treatment in Turkey. Methods: One hundred eight patients from 20 centers enrolled in the study. Starting from baseline, Gla-300 was self-administered subcutaneously and once daily in the evening. The primary outcome was the mean change in glycated hemoglobin A1c (HbA1c) from baseline to week 24. Results: The mean (±SD) Hb1Ac level of 9.4% (±0.8) at baseline decreased to 7.5% (±0.9) at week 12 (P <.1) and to 7.3% (±0.9) at week 24 (P <.1). Although none of the patients were within the target Hb1Ac level of ≤7% at baseline, the percentage of patients who achieved the target Hb1Ac level was 30.4% at week 12 and increased to 42.9% at week 24. Gla-300 treatment achieved the Hb1Ac target in 21 (19.4%) patients without experiencing a hypoglycemic event and in 27 (25.0%) patients who experienced at least one hypoglycemic event. For each self-monitoring blood glucose time point, significant improvements were observed as compared to baseline (P <.001). Statistically significant improvement (P <.001) was seen in the treatment satisfaction questionnaire – status version scores between baseline and week 24. Conclusion: This study indicated that Gla-300 is effective to provide a successful glycemic control with low risk of hypoglycemia added to OADs in insulin-naive patients with T2DM, and it has the potential to improve the quality of life of patients. © Author(s).